Production (Stage)
Seres Therapeutics, Inc.
MCRB
$7.09
$0.040.57%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -99.95% | -99.71% | 2,380.87% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -99.95% | -99.71% | 2,380.87% |
| Cost of Revenue | -45.95% | -73.65% | -83.18% | -85.77% | -69.22% |
| Gross Profit | -141.00% | -194.63% | -61.13% | 48.45% | 141.78% |
| SG&A Expenses | -30.48% | -33.07% | -37.53% | -29.45% | -8.60% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -222.93% | -145.32% | -140.64% | -134.88% | -62.31% |
| Total Operating Expenses | -39.59% | -45.85% | -49.41% | -47.14% | -27.56% |
| Operating Income | -75.25% | -20.59% | 1.46% | 0.72% | 74.54% |
| Income Before Tax | -7.69% | -31.98% | -12.71% | 7.77% | 76.55% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -7.69% | -31.98% | -12.71% | 7.77% | 76.55% |
| Earnings from Discontinued Operations | 778.69% | 1,091.63% | 1,943.11% | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 188.23% | 100.12% | 81.97% | -5.66% | 68.76% |
| EBIT | -75.25% | -20.59% | 1.46% | 0.72% | 74.54% |
| EBITDA | -85.62% | -22.72% | 1.36% | 0.74% | 76.41% |
| EPS Basic | 176.82% | 99.85% | 79.79% | 4.73% | 73.98% |
| Normalized Basic EPS | -45.60% | 3.12% | 2.65% | 17.16% | 80.62% |
| EPS Diluted | 175.02% | 99.14% | 79.55% | 4.85% | 73.75% |
| Normalized Diluted EPS | -43.65% | 3.85% | 3.19% | 17.56% | 80.36% |
| Average Basic Shares Outstanding | 22.04% | 21.40% | 14.47% | 10.92% | 14.26% |
| Average Diluted Shares Outstanding | 21.60% | 20.90% | 13.99% | 10.45% | 14.71% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |